Financing ·
Cocrystal Pharma, Inc. entered into a Securities Purchase Agreement on July 31, 2026, to sell 5,474,053 shares of…
COCPCocrystal Pharma, Inc.
Cocrystal Pharma, Inc. entered into a Securities Purchase Agreement on July 31, 2026, to sell 5,474,053 shares of common stock to OPKO Health, Inc., for gross proceeds of $5.0 million at $0.9134 per share. The transaction was conducted as an unregistered private placement under Regulation D. Proceeds will fund preclinical and clinical drug candidate programs, general corporate purposes, and working capital. Cocrystal Pharma is a biotechnology company developing novel antiviral therapeutics for norovirus, influenza, coronaviruses, and hepatitis C.